Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses: 2012-2024

Historic Accumulated Expenses for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $46.9 million.

  • Agios Pharmaceuticals' Accumulated Expenses rose 11.74% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 11.74%. This contributed to the annual value of $46.9 million for FY2024, which is 8.56% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Accumulated Expenses is $46.9 million, which was up 8.56% from $43.2 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Accumulated Expenses high stood at $46.9 million for FY2024, and its period low was $30.4 million during FY2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $43.2 million (2023), whereas its average is $40.1 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 42.04% in 2020, then surged by 42.23% in 2023.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Accumulated Expenses stood at $30.8 million in 2020, then grew by 3.79% to $32.0 million in 2021, then dropped by 5.06% to $30.4 million in 2022, then skyrocketed by 42.23% to $43.2 million in 2023, then increased by 8.56% to $46.9 million in 2024.